Whilst immune-mediated adverse drug reactions (ADRs) are rare, they are potentially life-threatening and present a major problem for clinicians. The underlying mechanisms that cause ADRs are not fully understood although genomewide association studies (GWAS) and case-control investigations have associated human leucocyte antigen (HLA) alleles as risk factors. There is evidence that a patient's ethnic background can have an impact on their risk of developing an ADR. This review summarizes the evidence related to HLA alleles and ADRs with particular focus on patient ethnicity. Our analysis indicated that many of the alleles which have been associated with ADRs are found at higher frequencies in Asian populations. The data also showed that many of the alleles that are reported to be statistically significantly associated with ADRs are in linkage disequilibrium with each other and that they form haplotypes specific to certain ethnicities indicating at least some of the allele associations may not be causal.
Introduction
Adverse drug reactions (ADRs) are undesired or harmful effects to the patient after the introduction of a drug treatment. Between 7 and 12% of hospital admissions and 5% of all hospital deaths in the United Kingdom are the result of ADRs Kongkaew et al., 2013; Sarker et al., 2015) . As defined by Rawlins & Thompson (1977) , ADRs are categorized into two main types: these are Type A or 'on target' and Type B or 'off target' also known as idiosyncratic reactions. Type A reactions are responses that are part of the drug's known pharmacological effects and are dose dependent, which means that the effects can be predicted. Conversely, Type B reactions, which are the focus for this review, are not seen in most patients being treated within the standard therapeutic dose range. These include immune-mediated ADRs which are rare, but can be life-threatening. The aetiology of these reactions is not completely understood and was previously thought to be unpredictable. However, more recently, genetic factors have been implicated. The strongest genetic associations for immune-mediated hypersensitivity reactions determined through genomewide association studies (GWAS) are with the human leucocyte antigens (HLA) (Daly et al., 2009; McCormack et al., 2011; Zhang et al., 2013a,b) . This has led to calls for an update to the definition of Type B reactions by moving away from referring to these as 'unpredictable' and 'dose independent' (Aronson & Ferner, 2015; Phillips, 2015) as at least some of these adverse reactions can be predicted based on the individual's genetic make-up; for example, Mallal et al., 2008 demonstrated that prospectively screening patients before administering abacavir reduced the occurrence of abacavir hypersensitivity. There are examples, described later in this review, where the association is not with a specific HLA allele but instead with a haplotype.
The HLA gene family is divided into three main classes (I, II and III), which have been implicated in the aetiology of ADRs, but there is limited knowledge about the precise mechanism of drug hypersensitivity and how the drugs interact with HLA molecules. The first two of these classes are involved with the ability of the immune system to distinguish between self and nonself by presenting peptide fragments to the immune system -class I proteins present peptides that are derived intracellularly, whilst class II HLAs present extracellularly derived peptide fragments. Class III proteins are involved with the complement system in host immunity where cytokines (such as TNF-a and HSP70) are released, producing an inflammatory response. An association has been demonstrated between TNF and HSP70 genes and carbamazepine (CBZ) -induced hypersensitivity reactions (Pirmohamed et al., 2001; Alfirevic et al., 2006a) . Both class I and class II proteins, if the presented peptide is recognized as foreign, can trigger an immune response.
The main proposed hypotheses to describe the HLA-ADR mechanisms are the hapten, the p-i concept (or pharmacological interaction with immune receptors) and the altered peptide repertoire models. The hapten model states that the drug covalently binds to the peptide fragment that will be presented by the major histocompatibility complex (MHC) molecule, whilst the p-i model proposes that the drug binds directly to the T-cell receptor or MHC molecule. The altered peptide repertoire model states that the drug binds noncovalently with the HLA protein within the antigen-binding cleft, and this binding alters the shape of the antigen-binding cleft and alters the repertoire of the peptide that is presented (Ostrov et al., 2012) . These changes are hypothesized to cause the host immune system to inappropriately trigger an immune response. As a specific example, abacavir, a reverse transcriptase inhibitor, has been shown to bind directly with the HLA-B*57:01 allele (Illing et al., 2012) . However, it is not known whether this mechanism of action explains other HLA-ADRs.
The HLA gene family is extremely diverse, with the IMGT/HLA database (Robinson et al., 2015) reporting 15 020 alleles currently known. Due to the great allelic diversity, a system has been developed for the nomenclature of the alleles. All alleles start with a 'HLA' prefix followed by a hyphen and the name of the gene (e.g. 'HLA-A'). To distinguish particular members of the gene, an asterisk (*) and a series of grouped numbers or fields are separated by colons. Alleles that share the same set of numbers for the first field are part of the same antigenic group, and the numbers for the second field identify the specific HLA protein; for example, HLA-B*57:01 is part of the same antigenic group as HLA-B*57:03 and only differ by two amino acid residues. The addition of 3rd and 4th fields (e.g. HLA-A*01:01:01:01) denotes synonymity within the proteincoding DNA and changes in the intronic regions, respectively. Although the HLA genetic diversity is important in providing protection against pathogens, this represents a problem for researchers and pharmaceutical companies as the risk allele and HLA haplotypes are rare and a large number of participants are required for well-powered clinical studies.
It has been observed that ethnicity plays a role in susceptibility to immune-mediated ADRs, linked with HLA allele frequency. For example, HLA-B*15:02 is a known risk factor for CBZ-induced Stevens-Johnson syndrome (SJS) in people of East and South-East Asian origin (Chung et al., 2004; Chang et al., 2011; Wang et al., 2011a,b; Kulkantrakorn et al., 2012; Cheung et al., 2013) ; as a result, the FDA recommends testing patients belonging to these ethnic groups for the HLA-B*15:02 allele before prescribing the drug (US Food & Drug Administration, 2013) . However, different HLA alleles (notably HLA-A*31:01) have been reported to be associated with CBZ-induced hypersensitivity in Caucasians (McCormack et al., 2011; Genin et al., 2014) indicating that ethnicity can influence risk profiles for a particular ADRs.
The aim of this review was to summarize the evidence of the HLA alleles associated with ADRs with particular focus on the variability of reported associations and how they differ based on the ethnicities of the patients. A systematic review of the literature was previously performed where ADR data and HLA associations were collected and stored within an HLA-ADR database (Ghattaoraya et al., 2016) as part of the Allele Frequency Net Database (AFND) website (Gonzalez-Galarza et al., 2015) . The HLA-ADR database is able to provide clinicians and researchers the ability to investigate ADRs associated with HLA alleles from a centralized resource. The database also captures information pertaining to the study cohort's allelic frequencies, ethnicity and disease phenotype (e.g. SJS).
Methods
In this review, we combined data deposited in the HLA-ADR database with the HLA haplotype frequency data within AFND website. The HLA-ADR database provided case-control data, and the AFND provided allele frequencies from healthy control populations. The frequencies for specific HLA alleles were obtained from AFND allele frequency search page using what is referred to in AFND as 'gold standard' population data -where the HLA allele information for the population is available at two fields or greater. The gold standard populations were chosen as Illing et al. (2012) have demonstrated that two-field resolution is required to distinguish between alleles that interact with drug molecules and those that do not. It is doubtful whether greater than two fields will yield additional information as the changes to the allele resolved at three or greater fields do not affect the final HLA protein molecule. Where possible, the allelic frequencies/percentages within a population referred to in this review were obtained from populations present in the database where the sample size was greater than 1000. Where this was not possible, the frequencies from populations with a smaller sample size were quoted instead and have been flagged as such in the text. In this review, we state the allele prevalence as frequencies within the population. The carrier frequencies would be approximately double the allele frequency as it is rare to find individuals who are homozygous across the MHC regions except in cases of consanguineous parentage. The data were analysed using a nonparametric, Kruskal-Wallis test to investigate associations across different haplotypes. This was performed with R version 3.2.2 (R Foundation for Statistical Computing, 2015, UK (https://cran.r-pro ject.org)) and with Bonferroni correction for multiple comparisons.
Frequencies for HLA haplotypes were obtained using the AFND haplotype frequency search tool. As haplotype data are limited, larger samples sizes (>1000) were preferred but not always possible; in all instances, we have stated the sample sizes within the text when referring to haplotype data. For this review, the following classifications for population demographics were used: (i) in the description of the studies, we assigned demographics using the country name/geographic location based on what was used in the original studies; (ii) for the statistical analysis of this review, the population groups have been simplified to three categories: African, Asian and European. The populations represented within AFND are classified based on the ancestry of the population as well as the country from which the population came from; for example, populations in the United States where the members were of Chinese origin are classed as Asian in the statistical analysis in this review. This enabled the analysis to investigate ethnicity without having to compensate for population nationality. The benefit to this simplification is to provide a higher statistical power for the analysis. However, this does mean some loss in granularity of the information.
The allelic and haplotype frequencies can be viewed visually with a map overlay using the abovementioned AFND allele frequency search and haplotype frequency search tools using the link: http:// www.allelefrequencies.net/.
Results

Antigout drugs
Allopurinol
Allopurinol is prescribed to treat patients with gout. Allopurinol hypersensitivity has been reported to be associated with the HLA-B*58:01 in several studies (Table S1 ) which examined Caucasian (Cristallo et al., 2011; Goncalo et al., 2013) , Han Chinese (Hung et al., 2005; Cao et al., 2012; Chiu et al., 2012) , Japanese (Hung et al., 2005) , Korean (Hung et al., 2005; Kaniwa et al., 2008; Niihara et al., 2013) and Thai (Kang et al., 2011) patients. Additionally, a case-control study by Lonjou et al. (2008) found the allele in hypersensitive individuals of South Asian, South American, European and African ancestries. The entry in Table S1 pertaining to this study has been marked as 'Diverse' for the ethnic group as the analysis did not separate the patient-control cohort by ethnicity. The above-mentioned studies also reported statistically significant associations with HLA-A*33:03, HLA-C*03:02 and HLA-DRB1*03:01. HLA-A*33:03 has been associated with allopurinol-hypersensitive patients in studies conducted with patients of Caucasian, Han Chinese and Korean origin. HLA-C*03:02 was found to be significant in Han Chinese and Korean patients. Interestingly, in both of the reporting studies (Hung et al. & Niihara et al.) , HLA-B*58:01 and HLA-A*33:03 were also found to be significantly associated. Using AFND HLA haplotype frequency search, HLA-C*03:02 has been found to form a haplotype with HLA-B*58:01 and HLA-A*33:03. This haplotype is relatively common in East Asian populations where the frequency has been reported to be as high as 8% of the population. By contrast, the frequency of the haplotype is <2% in European populations with the frequencies for these three alleles individually also <2%. The frequency for the haplotype was not available for African populations although the frequency of the individual alleles is 5-6% for HLA-A*33:03, 4% for HLA-B*58:01 and 2% for HLA-C*03:02.
HLA-DRB1*03:01 has been found in high linkage disequilibrium with HLA-A*33:03 and HLA-B*58:01 in East and South-East Asian populations where the frequency was reported as high as 6.6% in Taiwan. Additionally, the haplotype containing all the reported alleles was 4.4% in Southwest China. These haplotype data indicate that many of the reported alleles may not be causative alleles but have instead gained statistical significance in the reporting studies due to linkage. Given that the association for HLA-B*58:01 has been replicated across many ethnic groups, HLA-B*58:01 is a strong candidate for the true risk factor for allopurinol hypersensitivity.
Antituberculosis drugs
Standard treatment for tuberculosis (TB) involves a combination regime of multiple drugs including isoniazid, rifampicin, ethambutol and pyrazinamide. Therefore, it is difficult to isolate the causative agent in terms of antituberculosis drug-induced hypersensitivity. A study by Kim et al. (2013) investigated drug-induced hypersensitivity syndrome (DIHS) to antituberculosis drugs in Korean patients with TB who were receiving a combination regimen. The study reported HLA-C*04:01 as having a statistically significant association, P = 0.02, OR = 6.9 (2.2-20.11), for antituberculosis drug-induced hypersensitivity with 7 of 14 hypersensitive patients, 21/166 drug-tolerant controls and 62/485 healthy controls as reported to be carrying the HLA-C*04:01 allele. It is worth noting the relatively small patient sample size used in this investigation. Allele Frequency Net Database reports that this allele is not specific to any ethnic population and can be found, for example, at frequencies of 22.8% in a population of African ancestry, 19.3% in a Turkish population, 17.5% in Latin Americans and 13.6% in South Asians (where the sample sizes were >1000).
In addition to DIHS, antituberculosis drugs have been reported by Sharma et al. (2002) to be involved with HLA-associated hepatotoxicity within an Indian cohort. The study reported that HLA-DQB1*02:01 is a risk factor for antituberculosis-induced hepatotoxicity (P < 0.01) but also reports that carriers of the HLA-DQA1*01:02 allele are less likely to suffer from hepatotoxicity (P < 0.001) when compared to drugexposed controls. The HLA-DQB1*02:01 allele frequency is 19.9% in Indian populations (where sample sizes range from 58 to 202). The allele itself is not unique to this region where AFND reports observed frequencies of 59% in Sardinians, 22.8% in US population (of European origin), 22.3% in people of African ancestry and 21.8% in Latin Americans (sample size >1000).
Antibiotics
Dapsone
Dapsone is an antibiotic used for the treatment of leprosy. HLA-B*13:01 and HLA-C*03:04 were reported to be associated with dapsone-induced hypersensitivity in a Han Chinese patient cohort (Zhang et al., 2013a,b) . However, the study reported that the two alleles are in linkage disequilibrium, and when adjusted, only HLA-B*13:01 remained significantly associated. The HLA-B*13:01 allele is found predominantly around the region of East Asia, South-East Asia and Oceania where entries in AFND report the allele frequency is 6.4% in a Chinese population, 3.9% in a Vietnamese population and 2.8% in people originating from the Philippines where the sample sizes are >1000. Additionally, in smaller samples (approximately 100), the allele frequency has been observed to be as high as 25-28% in individuals from Papua New Guinea, Taiwan and Australia (Aborigine).
Amoxicillin-clavulanate
Adverse reactions induced by amoxicillin-clavulanate, a broad spectrum antibiotic, have been associated with HLA-DRB1*15:01, HLA-DRB5*01:01 and HLA-DQB1* 06:02 (Hautekeete et al., 1999) ; HLA-DRB1*15:01 (O'Donohue et al., 2000) ; HLA-A*02:01, HLA-DRB1* 15:01 and HLA-DQB1*06:02 (Lucena et al., 2011) ; and also HLA-A*30:02, HLA-DRB1*15:01 and HLA-DQB1*06:02 (Stephens et al., 2013) . In all of these studies, the study participants were Caucasian patients from Europe (Belgium, Scotland, mixed European (northwest European and Spanish subpopulations) and Spain, respectively). Notably, the HLA-DRB1*15:01 and HLA-DQB1*06:02 alleles were reported by all four investigations. Using the haplotype search in AFND, the HLA-DQB1*06:02 and HLA-DRB1*15:01 alleles are found together at >10% frequency in many diverse populations including Russian, Indian, European, East Asian and Australian Aborigine populations. Many more populations carry the same haplotype at relatively lower frequencies.
The HLA-A*02:01 allele does not appear to be in linkage disequilibrium with any other allele (class I or class II), so the association appears to be independent of the HLA-DRB1*15:01 and HLA-DQB1*06:02 haplotype. However, the Lucena et al. paper did report that the subpopulation of northwest European origin showed co-occurrence of HLA-A*02:01 and HLA-DQB1*06:02 which showed lower statistical association in the Spanish subpopulation.
The allele itself is very common and has been observed in high frequencies in a wide range of populations including European (Bosnia and Herzegovinia, the Netherlands, Croatia, Germany, Poland, United Kingdom, Spain, Italy and many others), Native American, Native Alaskan, Mexican and Chinese (Hong Kong). For all of these populations, the allele frequency is greater than 20% with sample sizes greater than 1000.
HLA-A*30:02 has not been observed to be in strong linkage disequilibrium with any particular class II HLA allele. A frequency search for just this allele reveals that it is common within populations originating from sub-Saharan Africa where it is found in approximately 6-7% where the sample size >1000 and ranges between 12 and 23% in samples sized between 44 and 230. The allele is also found in populations from North Africa (Morocco and Tunisia) and Mediterranean Europe (Portugal, Italy and Southern France) at approximately 5%. However, in these cases, the sample sizes were relatively small (less than 100). The frequency of HLA-A*30:02 in a UK-based population is comparatively lower; a frequency specific to Scotland was unavailable, so we have used a nearby Northern Ireland-based population (n = 1000) where the frequency is 1.2%. In a Spanish population (n = 1107), the frequency is 2.7%, and in Belgium (n = 99), the frequency is 1.6%.
Flucloxacillin
Flucloxacillin is a b-lactam class antibiotic which is used to treat mainly gram-positive bacterial infections. HLA-B*57:01 has been implicated in flucloxacillin-induced hepatotoxicity by Daly et al. (2009) which also reported that the HLA-DRB1*07:01 allele was statistically significantly more common in the study cases than in controls although HLA-B*57:01 was the strongest association (P = 8.97 9 10 À19 for HLA-B*57:01 against P = 1.9 9 10 À5 for HLA-DRB1*07:01). The study was conducted using Caucasian patients from the United Kingdom; however, the alleles themselves are found in many populations. HLA-B*57:01 is found (with a frequency of over 1%) in populations with Indian, European or East Asian ancestry, whilst HLA-DRB1*07:01 has a frequency of greater than 10% in populations of Indian, European, North African, East Asian, Native American and Latin American descent. It was also reported that a common haplotype containing HLA-B*57:01 consists of the alleles: HLA-A*01:01-HLA-B*57:01-HLA-C*06:02-HLA-DRB1*07:01-HLA-DQB1*03:03. The AFND haplotype search tool also supports high linkage disequilibrium with these alleles; specifically, AFND shows that the frequency of this haplotype is 9% in a population from Tunisia (sample size = 100), 2.16% in a South Asian population (n = 185 391), 1.49% in a SouthEast Asian population (n = 27 878) and 0.83% in a European population (n = 1 242 890). Overall, it is probable that HLA-B*57:01 is a true risk marker for flucloxacillin-induced hepatotoxicity as reported by the study with HLA-DRB1*07:01 gaining statistical significance due to the high co-occurrence of the alleles.
Sulfamethoxazole
Stevens-Johnson syndrome/toxic epidermal necrolysis has been reported (Kongpan et al., 2015) to be induced in patients taking sulfamethoxazole, a broad spectrum antibiotic. The study reported associations with HLA-B*15:02, HLA-C*06:02 and HLA-C*08:01 in a Thai patient cohort. As described above with CBZ, HLA-B*15:02 has a high allelic frequency in East Asian and South-East Asian populations. HLA-C*06:02 is not specific to an ethnic group and can be found at frequencies (where sample sizes are >1000) of 13.9% in South Asians, between 8 and 11% in many European populations, between 3 and 5% in East Asians and around 8% in populations of recent African ancestry. HLA-C*08:01 is particularly common in East and SouthEast Asian populations where it can be found at frequencies of 16.4% in Vietnamese, 10% Chinese and 7% in Japanese and Korean populations. It has also been reported in North American (Mexican, Native Alaska and Native American) population at a frequency between 1 and 3%.
A haplotype of HLA-B*15:02 and HLA-C*08:01 can be found in South-East Asian populations at frequencies of 22% in Philippines (sample size = 50) and 6-18% in Taiwan (sample sizes range between 50 and 102). There are no available data within the AFND website to analyse the co-occurrence of HLA-B*15:02 and HLA-C*06:02 alleles.
Antiepileptic drugs
Carbamazepine
Carbamazepine, an anticonvulsant used in the treatment of epilepsy, trigeminal neuralgia and bipolar disorders, is one of the most studied drugs for immune-mediated ADRs. The HLA-ADR database includes over 27 studies that investigated ADRs in association with this drug. In these studies, 22 HLA alleles at two-field resolution have been reported to be significantly associated (P < 0.05) with CBZ hypersensitivity (Fig. 1 ). The alleles HLA-A*31:01 and HLA-B*15:02 were reported as significant in the majority of these studies (11 and 19 papers, respectively). Figure 1 shows that the remaining 20 alleles have not been well replicated as they were only reported in three or fewer papers. For example, HLA-A*02:01 was reported to be statistically significant (P = 0.033) in Han Chinese patients ; however, the same allele was not replicated in a study by other groups also investigating Han Chinese Hsiao et al., 2014) or in Japanese and Korean patients Ozeki et al., 2011) . Fifteen of the 19 associations for CBZ HLA-B*15:02 hypersensitivity were from studies conducted in Han Chinese (n = 10), Thai (n = 3), Malay (n = 1) and Indian (n = 1) cohorts, with the remaining four associations reported in cohorts with diverse ethnicities. The HLA-B*15:02 allele is found at high frequency in East and South-East Asians (13.8% in Vietnamese population, 6.5% in Han Chinese and 4% in Filipinos -where sample sizes >1000 and between 14.8-35.8% in Han Chinese where the sample sizes were approximately 100). No associations have been reported between HLA-B*15:02 and SJS in Caucasians (Alfirevic et al., 2006b; Lonjou et al., 2008) , presumably because HLA-B*15:02 is found at near zero frequency in Europeans (data from AFND). By contrast, HLA-A*31:01 is a low-frequency allele found throughout the world (data from AFND). This is represented in the literature, where of the 11 significant associations for HLA-A*31:01 CBZ hypersensitivity, two were with Japanese patients, two for Korean, three for Han Chinese, two in European and two in a diverse cohort.
As well as analysing the data from AFND haplotype search tool, a Spearman's correlation analysis was performed on the alleles associated with CBZ-ADR (Table 1) . For this test, we only analysed the alleles which are statistically significant (P < 0.05) as reported by the literature sources contained within the HLA-ADR database and where more patients carried the allele compared to the control group -that is positive statistical significance indicating risk, we excluded alleles where one or more study reported the allele to have an apparent protective effect -statistical significance where more controls carried the allele compared to the hypersensitive patients. Here, only two alleles (HLA-A*31:01 and HLA-B*39:02) did not show evidence of linkage disequilibrium with the other alleles associated with CBZ hypersensitivity -indicating that these alleles may be independently associated with the ADR. With the remaining alleles, a more complex LD exists with varying degrees in the strength of the association. For example, HLA-A*02:01 showed weak linkage with HLA-DRB1*07:01 (0.05 < P > 0.01), whilst HLA-DRB1*12:02 seems to be in strong LD with four of the other alleles associated with CBZ-ADR (HLA-B*15:02, HLA-B*58:01, HLA-C*03:02 and HLA-C*08:01). This correlates with the observed haplotype frequency from AFND (Table S2) whereby HLA-B*15:02, HLA-C*08:01 and HLA-DRB1*12:02 are known to form a haplotype which is common in Asians. The highest frequencies for this haplotype are found in 5.6% of Vietnamese people (n = 43 540) and also 2.5% in a Chinese population (n = 99 672).
It is likely that both HLA-A*31:01 and HLA-B*15:02 are true positive associations given the number of independently confirmed reports. However, as these two alleles have differing peptide binding profiles and thus presumably quite different structural properties, it is unknown how the association for CBZ hypersensitivity is specific to HLA-A*31:01 and Figure 1 . HLA alleles which have been reported in the HLA-ADR database to be significantly associated with carbamazepine-induced adverse drug reactions. Black bars (positive y-axis) represent studies that report risk alleles, that is with a P-value <0.05 and where allele was found in proportionally more hypersensitive patients as compared to the control groups(s). The grey bars (negative y-axis) represent studies where the reported allele is suggestive to be protective, that is with a P-value <0.05 and where fewer patients exhibiting hypersensitive reactions to carbamazepine (CBZ) carried the allele compared to the control group(s). Note there is some overlap with the studies -where studies have reported multiple alleles as significant. In these cases, the graph shows these as separate entries. There is overlap between many of the flagged alleles -suggesting a potential haplotype with B*15:02/B*58:01, C*03:02/C*08:01, DRB1*12:02. Co-occurrence with these alleles, from different genes, has been observed in AFND (Table S3) . In bold are the significant positive correlations (nonparametric Spearman's correlation). (Hu et al., 2011) and HLA-B*38:02 (Lv et al., 2013) have been implicated in oxcarbazepine hypersensitivity. All of these studies were conducted in Han Chinese patient cohorts. However, none of these studies showed a statistically significant difference between the hypersensitive patients and the oxcarbazepine-exposed controls. The significant differences were reported for comparisons between the hypersensitive patients and the general population. The structural similarity between oxcarbazepine and CBZ may suggest a similar mechanism which causes hypersensitivity -especially because HLA-B*15:02 has been implicated for CBZ and suggested for oxcarbazepine. However, additional investigations into a large number of patients would be required to confirm this.
Phenytoin
Phenytoin is also used in the treatment of epilepsy. Three studies in our review reported a significant association between HLA-B*15:02 and phenytoininduced hypersensitivity in Han Chinese individuals (Hung et al., 2010; Cheung et al., 2013) and a Thai patient cohort (Locharernkul et al., 2008) . It was also reported by Hung et al. (2010) that the alleles, HLA-B*13:01, HLA-C*08:01 and HLA-DRB1*16:02, were associated with borderline significance. Another study by Manuyakorn et al. (2013) did not find a significant association for phenytoin-induced hypersensitivity in Thai patients carrying the HLA-B*15:02 allele. However, all four studies were underpowered; each patient cohort was relatively small comprising of between 4 and 26 hypersensitive patients. Recently, Bloch et al. (2014) performed a meta-analysis using pooled HLA-B*15:02 data from these four studies and reported a combined odds ratio 3.48 (95% CI: 1.75-6.91) which demonstrates that HLA-B*15:02 may be associated with phenytoin-induced SJS/TEN.
Lamotrigine HLA-B*15:02 has been reported to be a significant risk factor for patients being treated with the anticonvulsant drug, lamotrigine, in two meta-analyses (Hung et al., 2010; Bloch et al., 2014) . Both studies pooled data from primary studies to achieve sufficient statistical power -An et al. Li et al. (2013) reported increased risk in association with lamotrigine-induced maculopapular exanthema and the HLA-A*30:01 (P = 0.013) and HLA-B*13:02 (P = 0.013) alleles. The co-occurrence frequency with these two alleles as reported by AFND is between 1.8 and 8.9% with sample sizes ranging from 1282 to 99 672 in populations of Chinese or Korean origin, whilst this figure is below 1% in other ethnic groups. The study also reported a decreased occurrence of HLA-A*33:03 in lamotrigine-induced maculopapular exanthema patients compared with the control group (P = 0.048).
Antiretrovirals
Abacavir
Abacavir is a nucleoside reverse transcriptase inhibitor used in the treatment of HIV. Adverse reactions to abacavir have only thus far been reported in patients carrying the HLA-B*57:01 allele (Mallal et al., 2002; Hughes et al., 2004; Martin et al., 2004; Stekler et al., 2006; Rodr ıguez-N ovoa et al., 2007; Almeida et al., 2008; Rauch et al., 2008; Berka et al., 2012) and HLA-DRB1*07:01 (Rauch et al., 2008) alleles. The two alleles are known to be in high linkage disequilibrium; consequently, it is probable that statistical significance for HLA-DRB1*07:01 was reached in the Rauch et al. study due to this linkage with HLA-B*57:01. Rauch et al. reported that the association was stronger with HLA-B*57:01 (P < 0.001) compared to HLA-DRB1*07:01 (P = 0.01).
The HLA-B*57:01 allele is not unique to any specific ethnic population, and the incidence of abacavir hypersensitivity reflects this, with HLA-B*57:01 carriage and abacavir hypersensitivity being reported in patients across varying ethnic backgrounds. Additionally, abacavir has been demonstrated to directly interact with the F-pocket located in the antigen-binding cleft of the HLA-B*57:01 allele (Illing et al., 2012) . This would affect the binding specificity of the HLA peptide, and therefore, the presented peptide would be recognized as nonself, resulting in an immune response against healthy host cells.
Nevirapine
Three studies have reported significant association for HLA alleles with nevirapine (a non-nucleoside reverse transcriptase inhibitor) hypersensitivity (Chantarangsu et al., 2009; Carr et al., 2013; Phillips et al., 2013) .
Carr et al. reported an increased risk with black African (Malawi) patients carrying HLA-C*04:01.
Chantarangsu et al. reported HLA-B*35:05 as a risk factor but could not find a significant association for HLA-C*04:01 despite the allele being present in the patient cohort (Thai population). These two alleles are in linkage disequilibrium and form a haplotype group common to people of East and South-East Asian origin.
Phillips et al. reported several HLA alleles as significant; however, the P-values for these were not corrected for multiple comparisons. The study also performed multivariate analysis which indicated that HLA-B*58:01 and HLA-DRB1*01:02 showed an increased risk for nevirapine hypersensitivity and additionally a decreased risk with patients carrying HLA-B*15:10, HLA-B*58:02 and HLA-C*02:10. The evidence for linkage disequilibria for HLA-B*58:01 and HLA-DRB1*01:02 is remote as the co-occurrence frequency is less than 0.05% in any population within AFND. Contradictory to the Chantarangsu et al. report, Phillips et al. did not find HLA-B*35:05 allele in ethnically diverse patients to be statistically significant. Given that there is conflicting evidence for the alleles associated with nevirapine hypersensitivity, further investigations must be carried out to fully elucidate the association.
Although nevirapine and abacavir are both used in the treatment of HIV, one is a nucleoside analogue reverse transcriptase inhibitor and the other is a nonnucleoside reverse transcriptase inhibitor. The two drugs also have differing structures. This may explain why the ADRs with these two drugs are associated with different alleles.
Antirheumatics and NSAIDs
Aspirin
Aspirin is a widely used nonsteroidal anti-inflammatory drug (NSAID) and antirheumatic, antipyretic and analgesic agent that is available over the counter without the need of a prescription. In addition, low dose aspirin is often used for prevention of cardiovascular disease and in pregnancy, for prevention of pre-eclampsia. From our literature review, there were three studies that reported a significant association between HLA carriage and aspirin-induced urticaria (AIU) and aspirin-intolerant asthma (AIA) (Choi et al., 2004; Kim et al., 2005; Lee et al., 2009 ). Lee et al. reported a significant association between HLA-DPB1*03:01 and both AIU and AIA. Choi et al. only investigated AIA and also reported a significant association with the same allele. Kim et al. investigated both AIU and AIA, but were only able to report an association between this allele and AIU. The group also reported significant associations with other alleles (Table S3) . It is worth noting that all three of these studies were conducted in South Korea using a Korean patient cohort. Despite this, AFND shows that HLA-DPB1*03:01 is not specific to Korea (or even East Asia) and can be found at greater frequencies in European and also North and South American populations. HLA-DQB1*05:02 is a low-frequency allele but can be seen throughout the world with some increased frequencies in Mediterranean Europe and in East and South-East Asia.
Bucillamine
Proteinuria with bucillamine, an antirheumatic agent, has been associated with HLA-DRB1*08:02 (P = 1.96 9 10 À5 OR = 25.17, 95% CI: 7.98-79.38) and HLA-DQB1*04:02 (P = 2.69 9 10 4 OR = 10.35, 95% CI: 2.99-26.83) in Japanese patients (Furukawa et al., 2014) . The study reported that these alleles are in high linkage disequilibrium and were unable to reach the threshold for significance when attempting to separate these two alleles to determine which was the most probable for being associated with bucillamine hypersensitivity. The AFND HLA haplotype search also showed high linkage disequilibrium of the two alleles where the haplotype is very common in Latin Americans (up to 28% frequency in certain subpopulations in Mexico). In one Japanese subpopulation, the haplotype has a 10% frequency rate and is found in Russian subpopulations with up to 8% frequency. With these frequencies, the population sample sizes were small and ranged between 44 and 234.
Lumiracoxib
One study reported that lumiracoxib, a nonsteroidal anti-inflammatory drug, can cause hepatotoxicity associated with a common HLA haplotype: [HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB5*01:01, HLA-DQA1*01:02] (Singer et al., 2010) . Interestingly, the same haplotype has been associated with multiple sclerosis and in AFND, the haplotype is shown to have a prevalence of 1.1-9.3% and is only reported to be found in US Caucasians and Spanish populations. It is also worth noting that the HLA-DRB1*15:01 allele has also been associated as a risk factor for amoxicillin-clavulanate as mentioned earlier in this manuscript. Amoxicillin-clavulanate and lumiracoxib are different classes of drugs, so it is unlikely that the two drugs interact with HLA-DRB1*15:01 protein using the same mechanisms.
Sulfasalazine
Sulfasalazine is used in the treatment for inflammatory bowel diseases and rheumatoid arthritis. It has been reported to induce hypersensitivity reactions in Han Chinese patients who carry HLA-B*13:01, HLA-B*15:05 and HLA-B*39:01 . For HLA-B*13:01, the frequency of the allele is 6.3% in Chinese populations (sample size is slightly under 100 000) and 3.9% in Vietnamese populations (sample size = 43 540). In populations where the sample was smaller than 300, the allele can be found at frequencies of 28.3, 28 and 27% in Papua New Guinea, Taiwan and Australian Aborigine populations, respectively. Conversely, HLA-B*15:05 is a low occurring allele with the top three populations showing the greatest frequency, as reported in AFND, in Chinese (2.6%) and two Indian subpopulations (2 and 1.6%). HLA-B*39:01 can be found in Japanese populations at a frequency of approximately 3-4% and Native Americans at 3.4%, Croatians at 2.6% and Chinese at 1.9% where population sample sizes were >1000. Greater frequencies are observed when sample size restrictions are relaxed with the highest frequency being reported in several Taiwanese populations: Saisiat ethnic group at 54.9% and Tsou ethnic group at 24.5%.
Antipsychotics
Clozapine
Clozapine is an antipsychotic agent used to treat patients with treatment-resistant schizophrenia. Clozapine-induced agranulocytosis has been reported in two studies by the same group (Dettling et al., 2001a,b) which likely used the same patient and control groups of European origin. The initial study limited the investigation into HLA-B, HLA-DRB and HLA-DQB typing, whilst the full investigation typed these and also the HLA-C, HLA-DPB as well as the HLA-DRB1, DRB3, DRB4 and DRB5 loci. The authors reported HLA-DQB1*05:02, DRB5*02, HLA-C*07 and HLA-DPB*04:01 were associated with clozapine-induced agranulocytosis. However, their reporting of HLA was variable as they utilized old and current HLA nomenclature as well as a mix of high-and low-level resolution typing which limits the ability to incorporate these results within a meta-analysis as the allele and resolution data are not comparable with data from other studies.
HLA-DQB1*05:02 is the only allele reported as a risk factor for a clozapine-induced adverse response typed to two-field resolution (P = 0.006 and OR = 15.4, 95% CI: 1.72-138). The remainder cannot be determined to their specific gene/allele product. A recent GWAS performed by Goldstein et al. (2014) also reported that a SNP that is in strong linkage with HLA-DQB1*05:02 is a risk allele for agranulocytosis to clozapine. This study also reported that a SNP located in HLA-B played an important role, and the HLA-B*38, HLA-B*39 and HLA-B*67 alleles were offered as candidates to investigate further.
Antithrombotic drugs
Ticlopidine
Ticlopidine is a drug which is used for preventing thrombotic stroke in patients who are unable to take aspirin, for example the above-mentioned AIU and AIA, or if aspirin has previously failed to adequately treat the patient for a stroke. Hirata et al. (2008) reported HLA allele associations with ticlopidine-induced hepatotoxicity in Japanese patients with HLA-A*33:03, HLA-B*44:03, HLA-C*14:03, HLA-DRB1*13:02 and HLA-DQB1* 06:04. However, the study also reports that a haplotype consisting of all of these alleles is the second most common in the Japanese population and was present in 10 of the 14 hypersensitive individuals. A haplotype consisting of only the class I alleles from the above-mentioned list can be found in individuals from an East Asian origin (AFND).
Anticoagulants
Ximelagatran
Ximelagatran is an anticoagulant which was withdrawn from distribution in 2006 due to reported elevation of liver enzyme levels and hepatic damage in patients (European Medicines Agency, 2006 ). An investigation by Kindmark et al. (2008) into adverse reactions in Northern European patients who were treated with ximelagatran reported that drug-induced liver injury was significantly associated with HLA-DRB1*07:01 and HLA-DQA1*02. The study also reported that HLA-DQB1*02 was associated as 65% of the cases which carried the DRB1*07-DQA1*02 haplotype also possessed a DQB1*02 allele. The AFND haplotype frequency search tool shows that this haplotype can be found in many geographic regions including Africa, Asia, Australia (Aborigine) Europe and North America.
Anticancer drugs
Lapatinib
Lapatinib is used in the treatment of solid tumours including breast cancer and lung cancer. Hepatotoxicity induced by lapatinib has been reported to be associated with three HLA class II alleles: HLA-DQA1*02:01, HLA-DQB1*02:02 and HLA-DRB1*07:01 (Spraggs et al., 2011; Schaid et al., 2014) . Each of these studies was conducted in patients from diverse ethnic backgrounds. Furthermore, all three alleles have a wide geographic distribution and are not specific to a particular region in the world or ethnic group. Allele Frequency Net Database haplotype tool indicates that the co-occurrence of these alleles is 11.1% in a population of European ancestry (n = 1899) and with smaller sample sizes, 16.7% in a Moroccan population (n = 98), 10.2% in Tunisia (n = 100) and 6.6% in a South Korean population (n = 467).
More recently, an investigation by Parham et al. (2016) identified that HLA-DRB1*07:01 allele to be strongly associated with lapatinib-induced hepatotoxicity. The study did not report the association with either HLA-DQA1*02:01 or HLA-DQB1*02:02 which indicates that these alleles may have only been reported in the previous Schaid et al. (2014) and Table 2 . A truncated table showing the number of patients needed to be screened for the HLA allele(s) via genetic testing prior to prescribing the drug in order to prevent one ADR case. Data were taken from the HLA-ADR database (Ghattaoraya et al., 2016) part of allele frequencies net database (Gonzalez-Galarza et al., 2015) . The sensitivity, specificity, the numbers needed to screen to prevent one ADR case (shown in the table) and the formulae listed below (not shown in the table) have been calculated as part of this review. The method to determine the number needed to screen to prevent one ADR case was previously used in the Yip et al., 2012 study, but in short; the sensitivity and specificity are used to calculate the likelihood ratios (LR (2011) studies due to the high co-occurrence between these alleles and HLA-DRB1*07:01. It must also be acknowledged that HLA-DRB1*07:01 and serotypes that HLA-DQA1*02:01 and HLA-DQB1*02:02 belong to have also been associated with ximelagatran ADRs despite the dissimilar structures between the drugs.
Ocular glaucoma drug
Methazolamide
Methazolamide is a carbonic anhydrase inhibitor used to treat glaucoma. It has been reported to be associated with SJS/TEN in Han Chinese patients (Yang et al., 2016) . The study reported associations with the haplotype HLA-B*59:01-HLA-C*01:02. When looked at individually, the association for HLA-B*59:01 was calculated to have greater significance (P = 6.3 9 10
À7
; OR = 305.0; 95% CI: 11.3-8259.9) as compared to HLA-C*01:02 (P = 1.6 9 10
À2
; OR = 12.1; 95% CI: 1.3-111.7). The study reported that HLA-C*01:02 is a common allele in the Chinese population, and AFND reports allelic frequencies at 20% in people of Chinese ancestry, 17% in Japanese populations and 16% in Koreans and Vietnamese populations (where the sample sizes for each of these populations was greater than 10 000). However, the allele frequency for HLA-B*59:01 is much lower by comparison where it is found in 2% of Japanese and Korean populations and less than 1% in Chinese populations and at levels near zero in all other populations. The difference in the significance values between the two alleles can be explained as HLA-B*59:01 was reported to be carried by none of the drug-exposed controls and HLA-C*01:02 was found in 11 of 30 controls. As such, the study reported that HLA-B*59:01 is the most likely candidate for the risk factor for methazolamideinduced SJS/TEN. Table 2 presents a truncated list of the significant drug-HLA allele associations present within the HLA-ADR database as well as reporting the number of genetic screenings required to prevent one ADR case; this is of great importance when deciding the utility and health economic viability of pretreatment genetic screenings. For example, drugs for which the FDA and/or CPIC has recommended genetic screening prior to prescribing, screening patients for HLA-B*57:01 before the administration of abacavir requires between 20 and 74 screenings to prevent one ADR case. Additionally, for CBZ, screening patients of East, SouthEast and South Asian origin for HLA-B*15:02 would require between 10 000 and 32 000 screenings to prevent one case of SJS/TEN. Screening patients for HLA-A*31:01 from other backgrounds before treating with CBZ would require between 14 and 42 screenings to prevent one ADR case. These values above for the number of screenings relate to all CBZ -induced ADRs (e.g. SJS/TEN and maculopapular exanthema). The FDA and CPIC do not directly recommend genetic screenings for any of the other drugs. We are currently looking at the strength of the evidence and calculating the number needed to screen to prevent one ADR case to produce our suggestions as to which drug-allele combinations are of interest. Other factors which would need to be considered in these decisions that judge the utility and health economic costs for genetic screenings include the potential ramifications that the ADRs present to the patients, which in some cases can carry a risk of mortality. The full table can be viewed in supplementary section.
Analysis of all data
Our analysis of the literature has highlighted that although there are many HLA alleles which have been associated with ADRs, in some cases, the alleles are in linkage with each other. In addition to this, some of the associations have been made with both class I and class II alleles. However, relatively little haplotype data are available for alleles covering both class I and class II HLA alleles, as most of the available data focus on each class type. In the 91 studies that are present in the HLA-ADR systematic review, 56 studies focus only on class I HLA alleles, 18 studies focused solely with class II HLA alleles and only 17 studies typed patients across both of these classes. This limitation prevents a full understanding of the relationship that alleles in high linkage have in the context of ADRs. The solution to this would be to sequence patients across the entire MHC region so that all HLA alleles become available. Recently, there have been techniques that have been developed which aim to produce complete phasing of the MHC region (Selvaraj et al., 2015) , but the technology is still in its infancy.
The data featured in this review also suggest different prescribing decisions are required for each drug-ADR combination and this is partially influenced by the patient's ethnicity, which gives an indication as to the likelihood of the patient carrying a risk allele. For example, whilst our analysis of all the data indicates that both the HLA-A*31:01 and HLA-B*15:02 alleles have been strongly associated with CBZinduced ADRs, evidence is stronger to support pretreatment genotyping of patients for HLA-B*15:02 in Asians before prescribing the drug (Chen et al., 2011) . Comparatively, HLA-A*31:01 is an allele that can be found throughout many populations across the world at fairly low frequencies. To date, the United States Food and Drug Administration (FDA) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) have issued recommendations for the pretreatment genetic screening for four drugs including CBZ (Table 3) .
To investigate whether there are any trends that can be ascertained between the ethnic groups, we produced descriptive statistics (Table 4) and boxplots (Fig. 2) of the allele frequencies which have been associated with ADRs. These alleles were limited to those which have a strong association (P < 0.01) and/or have been independently replicated in two or more studies featured in the review. These boxplots have been grouped by the three major ethnic groups. Alleles that show significant differences between the three major ethnic groups as determined by a KruskalWallis test have been highlighted (Table 5) . Across the range of drugs covered in the review, there was an apparent trend that more of the alleles associated with ADRs were found in Asians: 6 of 33 HLA alleles reported in this article are statistically higher in prevalence in Asians, two in Africans and two for Europeans. This was particularly noticeable in patients treated with antiepileptic drugs who are of Asian origin, specifically with CBZ (43% of the associated alleles are found in higher frequencies in Asians), lamotrigine (33%) and phenytoin (67%). For these three drugs, the associations with alleles that show strong evidence/well replicated were either not specific to an ethnic group (neutral) or were associated with Asians; none of the alleles could be classed as strongly associated with Europeans or Africans.
Furthermore, the antiepileptic drugs phenytoin, CBZ and oxcarbazepine have ADRs associated with HLA-B*15:02. Given that these three drugs have aromatic structures, and combined with their relationship with HLA-B*15:02, this suggests that a similar mechanism could potentially be involved with the possibility of cross-reactivity with the antiepileptic drugs (Bloch et al., 2014) . The onset of cutaneous adverse reactions to antiepileptic drugs has been reported to be approximately five times greater in patients who have previously experienced an ADR with another antiepileptic drug; however, the rate of cross-reactivity varied between different drugs (Arif et al., 2007) . The study also recommended against giving patients phenytoin, CBZ and lamotrigine (two of which have ADRs associated with HLA-B*15:02) to patients with a history of antiepileptic-induced ADRs. All three drugs also have ADRs associated with HLA alleles that have higher frequencies in Asian populations. Additionally, Wang et al. (2011a,b) reported high cross-reactivity in Chinese patients for CBZ, oxcarbazepine, phenytoin and lamotrigine. The precise mechanisms which cause cross-reactivity of antiepileptic drugs are not fully understood. The greater number of associated alleles in Asians could be due to case-control study bias in the literature. Many of the studies tend to be conducted in Asia and Europe (approximately 60 and 23% of the included studies, respectively). As many of the hypersensitivity associations reported in the literature feature alleles that are in linkage disequilibria, this indicates that not all components of the haplotype are the true risk factor and that many of the alleles were found to be associated due to this strong linkage disequilibrium. Additionally, it is challenging to analyse allelic distribution over worldwide populations as some alleles are not present or are extremely rare in certain populations (e.g. HLA-B*15:02 is very rare outside of East Asians). This often makes it difficult to distinguish between alleles not present in the population versus alleles not tested. Consequently, whilst the Kruskal-Wallis analysis of population control data does show a skewing towards Asians, more data are required to form robust conclusions. The observed skewing towards Asians is possible because many drugs particularly in the past were likely developed in Europe and/or North America and where clinical trials were conducted with participants of European descent.
Discussion
In this review, it has been challenging to interpret results from different studies due to inconsistency in data reporting and sometimes low quality of Boxplots showing allele frequencies of alleles which are associated with ADRs. HLA alleles which have strong associations with ADRs (P < 0.01) and/or have been independently replicated are represented in this boxplot. The boxplots show the allele frequencies for these selected alleles and have been separated by ethnicity for the three major ethnic groups (Africans, Asians and Europeans). Alleles which show significant differences (as determined by the Kruskal-Wallis test performed in Table 5 ) have been marked. pharmacogenetic study design. Some reported alleles are not well replicated and appear to be significant in one study but nonsignificant in others. This is likely due to the studies using relatively small patient-control cohorts where a few patients can greatly influence the final results. This may be difficult to overcome as ADRs are rare, and therefore, it is difficult to recruit a sufficient number of ADR patients for a study.
This study is also prone to effects from publication bias. Firstly, whilst providing ample data for regions of East Asia and Europe, areas such as South America and Africa are poorly represented. This has left a general lack of data regarding ethnic groups from these regions. In addition, data sourced from our own HLA-ADR database for use in the analysis of this review lack data from unpublished studies. This limitation is caused by two major factors; the method with which the HLA-ADR database collected the data (by performing a literature search of published studies), and also due to the fact that only studies with at least one significant association tend to make publication. However, it is worth noting that the HLA-ADR database has made provisions to allow uncollected, unpublished data to be included into the database which will open up previously unavailable data to be included and used as part of various meta-analyses that is better representative of the population. Therefore, we strongly encourage researchers to share their data (both published and unpublished) even if there is no significant association found to allow the data to become available to all researchers and facilitate collaboration. It is of utmost importance, however, to introduce stringent quality control measures for reporting all published and unpublished data within the database to prevent incorrect clinical interpretation of results.
Conclusion
We believe that the following recommendations would greatly advance the field of immune-mediated ADRs. First, ensure that all studies perform two-field resolution or higher for genetic typing of patients. Secondly, it is necessary to replicate findings via collaborations to confirm associations. It is clear that evidence is strong for CBZ hypersensitivity in association with HLA-B*15:02 as there are multiple studies confirming the association; however, many of the other associations in this review only have one or a few studies which investigated that specific ADR which limits the utility of the information without the additional supporting evidence. Thirdly, in relation to the second point, conducting trans-ethnic studies would be important to assess causality of specific alleles and haplotypes in different populations. Finally, the cost of HLA typing has decreased considerably, mainly owed to advances in next-generation sequencing (NGS). The main advantages with NGS include less ambiguous HLA typing achieved via massive parallelization whereby single sequences are cloned to allow millions of strands to be simultaneously sequenced (Gabriel et al., 2014) . This is in contrast to current typing methods (e.g. sequence-specific oligonucleotide PCR and sequence-specific primer), which only amplify regions in exons 2 and 3 for class I genes and exon 2 for class II genes as this is where most of the known functional variability for HLA genes resides (Dunckley, 2012) . With these upcoming technological advances, phasing of the whole gene and/or MHC region will be possible when sequencing and will facilitate a broader understanding for the mechanisms of immune-mediated ADRs and allow for further investigation into the relationship between HLA alleles in phased haplotypes and patient ethnicity. If this is combined with an increase in the availability of cheaper to The allele frequencies were obtained from allele frequencies net database (AFND) for various subpopulations that belong to the major ethnic groups. The Kruskal-Wallis test was applied using the statistical package R version 3.2.2 where Bonferroni correction for multiple comparisons was applied. Comparisons that are significant (P < 0.05) after correction for multiple testing have been highlighted in Fig. 2 (boxplots) .
sequence HLA allele data, our understanding of the effect of ethnicity can be greatly enhanced as well as the field as a whole.
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